诱导化疗加三维适形放疗同步化疗不可手术的局部晚期非小细胞肺癌的疗效分析

目的 探讨诱导化疗+三维适形放疗(3DCRT)联合顺铂单药(每周方案)同步化疗不可手术的局部晚期非小细胞肺癌(NSCLC)的疗效和毒副反应.方法 76例局部晚期NSCLC患者(ⅢA期42例,ⅢB期34例)先接受2个周期的诱导化疗,再行3DCRT(DT 64～74 Gy,中位68 Gy)+同步顺铂(25 mg/m2,每周1次,共6～7周)化疗.结果 诱导化疗后2例达CR,32例达PR,有效(CR+PR)率为45%.同步化放疗后8例达CR,47例达PR,有效率为72%.全组中位生存期和中位无进展生存期分别为16.6个月和10.3个月,1、2、3年总生存率和无进展生存率分别为67%、35%、21%和42%、15%、6%.ⅢA期和ⅢB期的中位生存期、中位无进展生存期分别为19.7个月和15.6个月、10.8个月和9.4个月.主要的毒副反应为放射性食管炎、放射性肺炎、恶心呕吐和白细胞减少.治疗后45例肿瘤局部复发或(和)远处转移,其中4例照射野内复发,3例癌性胸水,38例远处转移.结论 诱导化疗后3DCRT+顺铂单药同步化放疗不可手术的局部晚期NSCLC的疗效和耐受性较好,可进一步研究.

Results of induction chemotherapy followed by concurrent chemoradiation in unresectable locally advanced non-small lung cancer

Objective To study the toxicity and efficacy of induction chemotherapy followed by concurrent cisplatin chemotherapy and three dimensional conformal radiotherapy (3DCRT) for inoperable locally advanced non-small cell lung cancer (LA-NSCLC). Methods Totally 76 patients with LA-NSCLC received two cycles induction chemotherapy followed by 3DCRT with a median dose of 68 Gy (64 to 74 Gy).During the 3DCRT, cisplatin (25 mg/m2, weekly) was given intravenously for 6-7 times. Results The CR rate, PR rate and overall response rate of induction chemotherapy were 3% ,42% and 45%. After the concurrent chemoradiation, the corresponding figures were 10%, 62% and 72%. The median survival time (MST) and median progression-free survival (PFS) of all patients were 16.6 months and 10.3 months. The 1-, 2- and 3-year overall survival (OS) and PFS rates were 67% , 35% , 21% and 42% , 15%, 6%. Of patients with stage ⅢA and stage ⅢB disease,the MST were 19.7 months and 15.6 months, the PFS were 10.8 months and 9.4 months. The major treatment-related toxicities included radiation esophagitis, radiation pneumonitis, nausea ( or vomiting) and leukopenia. The major pattern of treatment failure was distant metastasis. Forty-five patients (59%) experienced the local recurrence or/and distant metastasis, including 4 (9%) with in-field failure, 38 (84%) distant metastasis and 3 (7%) malignant pleural effusion. Conclusions Induction chemotherapy followed by concurrent weekly cisplatin and 3DCRT for inoperable locally advanced NSCLC results in encouraging outcomes and acceptable tolerance.